Altamira Therapeutics Ltd. Cash And Cash Equivalents
Altamira Therapeutics Ltd. (CYTOF) had Cash And Cash Equivalents of $3.75 thousand as of 2025-06-30, per its 6-K filed 2025-08-29.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2025-08-29
- 2023-12-31: Cash And Cash Equivalents 617.41K CHF.
- 2023-06-30: Cash And Cash Equivalents 49.57K CHF.
- 2022-12-31: Cash And Cash Equivalents 15.39K CHF.
- 2022-06-30: Cash And Cash Equivalents 372.65K CHF.
CHF
| Period end | Cash And Cash Equivalents |
|---|---|
| 2023-12-31 | 617.41K CHF 20-F/A · filed 2024-04-22 |
| 2023-06-30 | 49.57K CHF 6-K · filed 2023-09-12 |
| 2022-12-31 | 15.39K CHF 20-F/A · filed 2024-04-22 |
| 2022-06-30 | 372.65K CHF 6-K · filed 2023-09-12 |
| 2021-12-31 | 984.19K CHF 20-F/A · filed 2024-04-22 |
| 2021-06-30 | 8.47M CHF 6-K/A · filed 2023-08-21 |
| 2020-12-31 | 11.26M CHF 20-F/A · filed 2024-04-22 |
| 2020-06-30 | 39.94K CHF 6-K · filed 2021-09-08 |
| 2019-12-31 | 1.38M CHF 20-F · filed 2023-05-16 |
| 2019-06-30 | 5.79M CHF 6-K/A · filed 2020-09-17 |
| 2018-12-31 | 5.39M CHF 20-F · filed 2022-04-12 |
| 2018-06-30 | 4.42M CHF 6-K · filed 2019-08-15 |
| 2017-12-31 | 14.97M CHF 20-F · filed 2021-03-31 |
| 2016-12-31 | 32.44M CHF 20-F · filed 2020-04-16 |
| 2015-12-31 | 50.24M CHF 20-F · filed 2019-03-14 |
| 2014-12-31 | 56.93M CHF 20-F · filed 2018-03-22 |
USD
| Period end | Cash And Cash Equivalents |
|---|---|
| 2025-06-30 | $3.75K 6-K · filed 2025-08-29 |
| 2024-12-31 | $998.62K 6-K · filed 2025-08-29 |
| 2024-06-30 | $65.45K 6-K · filed 2025-08-29 |
| 2023-12-31 | $733.70K 6-K · filed 2025-08-29 |
| 2023-06-30 | $55.38K 6-K · filed 2024-09-24 |
| 2023-01-01 | $16.64K 20-F · filed 2025-04-30 |
| 2022-12-31 | $16.64K 20-F · filed 2025-04-30 |
| 2021-12-31 | $1.08M 20-F · filed 2025-04-30 |